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Abstract
Background: Higher standardized uptake value (SUV) detected by 18F-fluorodeoxyglucose positron emission
tomography/computed tomography (FDG PET/CT) correlates with proliferation of primary breast cancer. The
purpose of this study is to identify specific molecules upregulated in primary breast cancers with a high SUV and
to examine their clinical significance.
Methods: We compared mRNA expression profiles between 14 tumors with low SUVs and 24 tumors with high
SUVs by cDNA microarray. We identified centromere protein F (CENP-F) and CDC6 were upregulated in
tumors with high SUVs. RT-PCR and immunohistochemical analyses were performed to validate these data.
Clinical implication of CENP-F and CDC6 was examined for 253 archival breast cancers by the tissue microarray.
Results: The relative ratios of CENP-F and CDC6 expression levels to β-actin were confirmed to be significantly
h i g h e r  i n  h i g h  S U V  t u m o r s  t h a n  i n  l o w  S U V  t u m o r s  ( p  = 0.027 and 0.025, respectively) by RT-PCR. In
immunohistochemical analysis of 47 node-negative tumors, the CENP-F expression was significantly higher in the
high SUV tumors (74%) than the low SUV tumors (45%) (p = 0.04), but membranous and cytoplasmic CDC6
expressions did not significantly differ between both groups (p = 0.9 each). By the tissue microarray, CENP-F (HR
= 2.94) as well as tumor size (HR = 4.49), nodal positivity (HR = 4.1), and Ki67 (HR = 2.05) showed independent
impact on the patients' prognosis.
Conclusion: High CENP-F expression, correlated with high SUV, was the prognostic indicators of primary breast
cancer. Tumoral SUV levels may serve as a pretherapeutic indicator of aggressiveness of breast cancer.
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Background
Although a majority of patients with primary breast can-
cer are cured by locoregional treatment with or without
systemic therapy, approximately 10–30% of these
patients experience recurrence of the cancer [1]. Research-
ers have suggested various biomarkers or risk categories of
breast cancer to reliably identify high-risk patients, who
would require chemotherapy, and low-risk patients, who
can be treated without chemotherapy [2]. Nodal status is
the important prognostic and predictive factors in the
treatment of primary breast cancer; however, there are still
no definitive criteria that can identify high-risk patients
with primary breast cancer, especially those with node-
negative (pN0) breast cancer.
Currently, primary systemic therapy (PST) is widely prac-
ticed as a standard therapy for patients with early-stage
breast cancer [3], but it is difficult to preoperatively iden-
tify high-risk patients in the PST setting because available
information obtained from core needle biopsy specimens
is limited. Although molecular biology tools such as
Oncotype DX™ or the 70-gene expression classifier identi-
fied by DNA microarray analysis (MammaPrint®) are
going to be used widely for risk evaluation, utility of these
tools has not been confirmed with primary breast cancer
in the PST setting [4-6]. Therefore, we need new tools that
can preoperatively and accurately predict the prognosis of
patients with early-stage breast cancer.
FDG PET/CT is a noninvasive imaging device widely used
for the detection and staging of breast cancer[7]. FDG
uptake on PET, quantified by the standardized uptake
value (SUV), is a highly reproducible parameter of tumor
glucose metabolism [8].
We previously reported that high SUV levels (4.0 or more)
in primary breast tumors significantly correlated with
higher nuclear grades and poorer prognoses of primary
breast tumors [9]. We suggested that the tumoral SUV
detected by FDG PET/CT could be a preoperative tool to
predict high-risk patients with primary breast cancer.
In fact, primary cancers with high SUV detected by FDG
PET/CT correlated with the parameters of rapid cellular
proliferation, e.g., mitotic counts and Ki67 index, and
exhibited poorer clinical outcome than those with low
SUV. Such correlation was reported in various cancers,
including non-small-cell lung cancer, ovarian cancer, and
breast cancer [10-13]. When novel prognostic molecules
correlated with high SUV are identified, it might be very
helpful for the accurate preoperative prediction of high-
risk patients with early breast cancer.
The present study aimed at detecting novel candidate
genes from primary breast cancers with high SUV. We
compared mRNA expression profiles and protein expres-
sions of several specific molecules between primary breast
cancer with high SUV and those with low SUV by means
of cDNA microarray and immunohistochemistry. We also
evaluated whether the candidate genes identified by the
cDNA microarray correlated with the clinical outcome.
Furthermore, we discussed whether the SUV categories by
FDG PET/CT are useful to predict tumor proliferation and
to identify patients having high-risk primary breast cancer
before the systemic therapy or surgery.
Methods
Patient characteristics
This study was approved by the institutional review com-
mittee of the National Defense Medical College, Japan.
Informed consent was obtained from each eligible
patient. Primary breast cancer was histopathologically
diagnosed on a core needle biopsy. Patients who did not
exhibit evidence of distant metastatic spread in results of
X-ray, ultrasonography, or FDG PET/CT were eligible as
operable candidates for the treatment of primary breast
cancer. Pregnant patients, patients with a history of insu-
lin-dependent diabetes mellitus from clinical notes, or
those who had previously received treatment to breast
cancer were excluded from assessment with FDG PET/CT.
These patients did not receive any systemic therapy before
surgery. FDG PET/CT examination was performed at an
interval of 2 weeks or more after the core needle biopsy
(CNB). All the patients underwent surgery within 6 weeks
after the FDG PET/CT examination.
Surgical specimens were obtained from patients who under-
went mastectomy or lumpectomy for primary breast cancer.
Initially, a total of 48 samples comprising 24 high SUV
tumors and other 24 low SUV tumors, that were matched
with regard to pT and pN factors, were subjected to RNA iso-
lation. A sufficient volume of total RNA were extracted from
all 24 samples of high SUV tumors and 14 (58%) of 24 sam-
ples of low SUV tumors. Therefore, a total of 38 samples were
used for the cDNA microarray study.
These tissue samples of primary breast cancer in the 38
patients were subjected to cDNA microarray and quantita-
tive RT-PCR analyses. The age of patients included in this
study ranged from 36 to 81 years (mean, 56 years). The
disease was in stage I in 18 patients (T1N0M0 in 18) and
stage II in 20 (T1N1M0 in 4, T2N0M0 in 8, and T2N1M0
in 8). All the 38 tumors were histologically invasive ductal
carcinoma. All patients underwent FDG PET/CT to evalu-
ate the primary tumor and metastatic site of the disease.
FDG PET/CT and quantification of FDG uptake in primary 
breast cancer
All patients underwent FDG PET/CT scans (Biograph LSO
Emotion, Siemens) at the Tokorozawa PET DiagnosticBMC Cancer 2008, 8:384 http://www.biomedcentral.com/1471-2407/8/384
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Imaging Clinic (Tokorozawa, Japan). Patients fasted for at
least 6 h before the FDG PET/CT study. One hour after the
intravenous administration of 3.7 Mbq/kg FDG, a trans-
mission scan using CT for attenuation correction and ana-
tomical imaging was acquired for 90 s. Intravenous
contrast was not administered to patients for the CT por-
tion of the FDG PET/CT.
Back projection images were obtained after applying a
Gaussian filter. The spatial resolution of the reconstructed
images was 6.0–7.0 mm in the craniocaudal direction,
6.3–7.1 mm in the right-left direction, and 6.3–7.1 mm in
the anterior-posterior direction.
SUV is defined as the decay-corrected tissue activity
divided by the injected dose per patient body[9]. A region
of interest (ROI) was placed in the primary lesion includ-
ing the highest uptake area (circular ROI, 1 cm in diame-
ter), and the SUV maximum in the ROI was calculated.
SUV was calculated using the following formula: SUV =
activity in ROI (MBq/ml)/injected dose (MBq/kg body
weight).
We divided these 38 tumors into 2 groups based on the
characteristics revealed in the FDG PET/CT. The low SUV
group consisted of patients with a primary tumor with an
SUV less than 4.0, whereas the high SUV group consisted
of patients with a primary tumor with an SUV of 4.0 or
greater. There were 14 tumors in the former group and 24
tumors in latter group.
Clinicopathological features of patients classified accord-
ing to SUV are shown in Table 1. Regarding to age, pT-fac-
tor, pN-factor, nuclear grade, ER, and HER2, no statistical
difference were detected between 2 groups.
RNA extraction and cDNA microarray analysis
The tissue samples obtained from surgical specimens were
immediately frozen in liquid nitrogen until RNA isola-
tion. Total RNA was extracted from 14 tumor samples
with low SUV and 24 tumors samples with high SUV by
using ISOGEN (Nippon Gene, Tokyo, Japan). The
amount and quality of RNA were assessed using a UV
spectrophotometer. cDNA microarray analysis was per-
formed using IntelliGene® Human Cancer CHIP Ver. 4.0
(Takara, Kusatsu-shi, Japan). Briefly, 4 μg of total RNA was
used for double-stranded cDNA probe synthesis with a T7
oligo (dT) primer. Each cDNA fragment was then sub-
jected to RT amplification that incorporated aminoally-
UTP (Ambion), which was coupled with either Cy3 or
Cy5 (Amersham Biosciences), and purified through a
microcon 30 spin colum (Millipore). The generated RNA
was used as a probe for hybridization in IntelliGene®
Human Cancer CHIP Ver. 4.0, as previously
described[14]. The cDNA chip arrayed and immobilized
with approximately 890 cDNA fragments of human
genes, which are composed of approximately 590 kinds of
identified human oncogenes and approximately 300
kinds of the cDNA fragments prescreened by the differen-
tial display method between cancer tissue and corre-
sponding normal tissue. For each gene identified by the
differential display method, a cDNA region approxi-
mately 300 bp in length, which has minimal homology
with other genes registered in the cDNA database, was
spotted on the DNA microarray chip [15].
We defined genes with Cy3:Cy5 ratios of 3.0 or greater in
signal intensity as up-regulated genes because of the fol-
lowing reasons:
We first identified 20 genes, that showed the Cy3:Cy5
ratios of 1.7 or greater, as the candidate genes that were
Table 1: Clinicopathological features of 38 patients with primary breast cancer subjected to cDNA microarray and RT-PCR analyses
Number of patients
Parameters High SUV group
(n = 24)
Low SUV group
(n = 14)
p-value
SUV Mean± SD 7.2± 2.5 2.3± 0.9 <0.0001
Age Mean± SD 56.9± 14.1 59.8± 10.3 0.5
T-factor T1 13 9 0.5
T2 11 5
N-factor N0 16 10 0.8
N+ 8 4
Nuclear grade 1,2 10 11 0.06
31 43
ER - 7 1 0.1
+1 71 3
HER2 0,1+,2+ (FISH-) 19 13 0.3
3+ or FISH+ 5 1
Abbreviations; SUV, Standardized uptake value; ER, Estrogen receptor; HER2, c-erbB2; FISH, Fluorescence in situ hybridization; SD, standard 
deviationBMC Cancer 2008, 8:384 http://www.biomedcentral.com/1471-2407/8/384
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upregulated in the high SUV tumors (Table 2). In the two
genes that showed the Cy3:Cy5 ratios of 3.0 or greater, i.e.,
CENP-F and CDC6, we could validate their upregulation
in the high SUV tumors by RT-PCR as mentioned below.
On the other hand, in other candidate genes, e.g., gtf2b
(Cy3:Cy5 ratio 2.79), KRT5 (Cy3:Cy5 ratio 2.05), MMP9
(Cy3:Cy5 ratio 1.95), and PLAU (Cy3:Cy5 ratio 1.78),
their up-regulation could not be validated by means of
RT-PCR. Furthermore, a housekeeping gene GAPDH was
also ranked in the candidate genes with a Cy3:Cy5 ratio of
2.18 by cDNA microarray analysis. Therefore, we chose
the cut-off value of 3.0.
Validation of microarray data with RT-PCR
Two candidate genes (CENP-F and CDC6) detected on the
cDNA microarray screening were selected for the valida-
tion of the microarray results. Total RNA was extracted
from 100 μg of frozen tumor tissue obtained from each
primary breast cancer specimens. Reverse transcription for
cDNA was performed from 5 μg of total RNA. PCR was
performed using dNTP, Taq polymerase primer pair, and
cDNA using a thermal cycler. The primer sequences of
CENP-F were 5'-CGAAGAACAACCATGGCAACTCG-3'
and 5'-TTCTCGGAGGATGGTGCCTGAAT-3'. The primer
sequences of CDC6 were 5'-GCGATGACAACCTAT-
GCAACAC-3' and 5'-TTGGTGGAGAACAAGGAGGTAAA-
3'.
The expression value for each gene was normalized
against that of β-actin. Results are presented as the mean
± standard error (SE). Statistical analysis was performed
using the Student's t test.
Case selection for a validation study
To validate the expression levels of candidate genes at the
protein level, we performed an immunohistochemical
study. A cohort of 47 patients was selected from those
who received surgical therapy to node-negative primary
breast cancer from August through December in 2006.
The primary cancers exhibited low SUV (mean 2.2 ± 1.0
SD) in 20 patients and high SUV (mean 7.8 ± 3.4 SD) in
27. The patients' ages (mean 53.2 ± 10.0 SD and mean
55.6 ± 10.1 SD, respectively), tumor size (mean 2.4 ± 2.9
SD and mean 3.1 ± 2.1 SD, respectively), ER (positive in
85% and 59%, respectively), and HER2 status (positive in
10% and 26%, respectively) did not differ significantly
Table 2: Twenty genes that were identified as upregulated in tumors of the high SUV group compared with those of the low SUV 
group
Rank Symbol Gene name Genbank Accession No. High/Low ratioa) Function
1 CENPF centromere protein F (mitosin) NM016343 3.66 cell-cycle regulation
2 CDC6 cell division cycle 6 NM001254 3.36 cell-cycle regulation
3 gtf2b general transcription factor IIB M76766 2.79 transcription initiation
4 Fgr Gardner-Rasheed feline sarcoma viral 
oncogene homolog
NM005248 2.49 mast cell activation
5 GAPDHS glyceraldehyde-3-
phosphate_dehydrogenase
NM002046 2.18 carbohydrate metabolism
6 Oaz1 ornithine decarboxylase 1 NM002539 2.14 regulation of polyamine synthesis
7 ACTA1 actin, alpha 2, smooth muscle, aorta NM001613 2.1 cell motility, structure
8 KRT5 keratin 5 NM000424 2.05 type 2 cytokeratine
9 RCC1 chromosome condensation 1 NM001269 2.03 cell-cycle regulation
10 BAK1 BCL2-antagonist/killer 1 NM001188 1.96 anti- or pro-apoptotic regulators
11 MMP9 matrix metalloproteinase 9 NM004994 1.95 embryonic development and tissue 
remodeling
12 MAP2K5 mitogen-activated protein kinase kinase 
5
NM002757 1.94 Kinase related to signal cascade
13 MAP2K2 mitogen-activated protein kinase kinase 
2
NM030662 1.93 Kinase related to signal cascade
14 Litaf LPS-induced TNF-alpha factor NM004862 1.9 proinflammatory cytokine
15 COL7A1 collagen, type VII, alpha 1 NM000094 1.85 epithelial adhesion complex
16 HRMT1L2 HMT1 (hnRNP methyltransferase, S. 
cerevisiae)-like 2
NM001536 1.84 catalyzes protein methyl-transferase 
modification
17 CXCL13 small inducible cytokine B subfamily, 
member 13
NM006419 1.82 migration of B lymphocytes
18 PLAU plasminogen activator, urokinase NM002658 1.78 serine protease
19 CDC37 cell division cycle 37 NM007065 1.77 cell-cycle regulation
20 Pax paxillin NM002859 1.74 cell adhesion of the extracellular 
matrix
a) High/low ratio; the ratio of the quantitative value of the gene expression in tumors of the high SUV group to that in tumors of the low SUV 
group.BMC Cancer 2008, 8:384 http://www.biomedcentral.com/1471-2407/8/384
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between the low- and high-SUV groups (Table 3). Molec-
ular subtypes were also evaluated as described below.
Tissue microarray (TMA) construction
Hematoxylin and eosin (HE)-stained sections of archival
pathological primary breast cancer specimens were
reviewed. These specimens were resected from patients
between January 1990 and December 1995. The histolog-
ical diagnosis including histological type and nuclear
grade was confirmed for all cases. For the 253 available
cases of primary breast cancer, two tissue cores with a
diameter of 2.0 mm were punched out from representa-
tive areas in 253 archival pathological tissue blocks. TMA
was constructed by the method described previously [16].
One TMA block contained a maximum of 40 tissue cores,
and 8 TMA sets were prepared for the present study. We
then cut 4-μm-thick sections from the blocks.
Immunohistochemistry
We cut 4-μm thick sections from routinely processed, for-
malin-fixed paraffin-embedded tissue blocks or TMA
blocks and mounted them on silane-coated slides. Immu-
nohistochemistry with anti-human antibodies against
centromere protein F (CENP-F) (ab90, 1/200 dilution;
Abcam, Cambridge, MA), phosphorylated-CDC6-S54
(CDC6) (AP3058a, 1/200 dilution; Abgent, San Diego,
CA), Ki67 (clone: MIB1, ready-to-use, Dako, Glostrup,
Denmark), and p53 (clone: DO-7, 1/200 dilution, Dako)
was performed by the streptavidin-biotin-peroxidase
complex method or the EnVision (Dako) method. To
assess CENP-F and CDC6 expressions, normal skin tissues
were used as the positive control. ER and HER2 were also
immunohistochemically analyzed using specific primary
antibodies (Dako) as described previously [16,17].
Staining results were independently assessed by 2 of 3
observers (S.U, S.Y, and H.T). When there was a difference
in judgment, consensus was reached over a discussion
microscope. Immunohistochemical results were assessed
based on both the intensity and proportion of cancer cells
with nuclear, cytoplasmic, and/or membrane staining.
The intensity of nuclear staining were 0 (null), 1+ (faint),
and 2+ (strong). Positivity was defined as nuclear staining
of 10% or more cancer cells with a strong intensity for
CENP-F, Ki67, p53, ER, and PgR. For CDC6, expression
patterns in cancer cells were classified into nuclear and
cytoplasmic. The detection of nuclear and cytoplasmic
stainings in 10% or more cancer cells was defined as pos-
itivity of nuclear CDC6 (nCDC6) and cytoplasmic CDC6
(cCDC6), respectively. For HER2, a score of 3+ detected by
Herceptest, or gene amplification detected by means of
fluorescence in situ hybridization were defined as positive
[16]. According to the status of ER and HER2, the 47 cases
were classified into molecular subtypes, i.e., ER+/HER2-
Table 3: Comparision of clinicopathological features of patients and immunohistochemical results of biomarkers between the low SUV 
group and the high SUV group in 47 cases of node-negative breast cancer
Parameters High SUV group
(n = 27)
Low SUV group
(n = 20)
p-value
SUV Ave± SD 7.8± 3.4 2.2± 1.0 <0.0001
Age Ave± SD 55.6± 10.1 53.2± 10.0 0.42
Tumor size Ave± SD 3.1± 2.1 2.4± 2.9 0.33
Nuclear grade 1 and 2 8 15 0.004
31 95
ER <10% 11 3 0.06
10% &#x2266; 16 17
HER2 0,1+,2+ (FISH-) 20 18 0.17
3+ or FISH+ 7 2
CENP-F Positive 20 9 0.04
Negative 7 11
n-CDC6 Positive 13 10 0.9
Negative 10 10
c-CDC6 Positive 9 7 0.9
Negative 18 13
Ki67 Positive 25 12 0.02
Negative 2 8
p53 Positive 9 2 0.06
Negative 18 18
Molecular subtypes Luminal A 16 17 0.05
HER2 7 2
Triple negative 4 1
Abbreviations; SUV, Standardized uptake value; ER, Estrogen receptor; HER2, c-erbB2; FISH, Fluorescence in situ hybridization; SD, standard 
deviation; CENP-F, Centromere protein-F; SUV, Standardized uptake value; n-CDC6, nuclear staining of Cell devision cycle 6; c-CDC6, cytoplasmic 
staining of Cell devision cycle 6BMC Cancer 2008, 8:384 http://www.biomedcentral.com/1471-2407/8/384
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(luminal A subtype), ER+/HER2+ (luminal B subtype),
ER-/HER2+ (HER2 subtype), and ER-/HER2- (triple-nega-
tive subtype).
Statistical analysis
Statistical analysis was performed using StatView 6.0 soft-
ware. Positivity of molecular expression was compared
between the groups. Cox's proportional hazard regression
models were used to assess the prognostic contribution of
clinical variables and biomarkers. Hazard ratios were ver-
ified by all-possible-subset analyses. A p value of less than
0.05 was considered significant.
Results
Identification of genes correlated by tumoral SUV
We calculated the ratio of the quantitative value of gene
expression in the high SUV group to that in the low SUV
group for each gene by cDNA microarray analysis. We
identified 20 genes, the expression levels of which were
1.7-fold or higher in the high SUV group than in the low
SUV group (Table 2). Of these, the expression levels of the
CENP-F and CDC6 were threefold or higher in the high
SUV group than in the low-SUV group (Table 2). Quanti-
tative RT-PCR analysis using total RNA identical to that
used for cDNA microarray analysis was performed.
Results revealed that the average ratios of CENP-F and
CDC6 expressions relative to that of β-actin expression
were significantly higher in the high SUV group (1.6 ± 0.3
SE and 0.9 ± 0.1 SE) than in the low SUV group (0.8 ± 0.3
SE and 0.5 ± 0.1 SE) (p = 0.027 and 0.025, respectively)
(Figure 1).
Validation of gene expression data by 
immunohistochemistry
We assessed a cohort of 47 breast cancers for validation by
immunohistochemistry. Of these, 20 cancers with low
SUV comprised 15 tumors of nuclear grade 1/2 and 5 of
nuclear grade 3, while 27 cancers with high SUV included
8 tumors of nuclear grade 1/2 and 19 of nuclear grade 3
(Table 2). Immunohistochemical results of 20 low SUV
and 27 high SUV cancers for CENP-F, CDC6, Ki67, p53
and molecular subtypes are also shown in Table 3.
CENP-F is a nuclear protein regulating cell cycle that is
overexpressed in the M phase. The positivity of the CENP-
F expression in the high SUV group (74%, 20 of 27) was
significantly higher than that in the low SUV group (45%,
9 of 20) (p = 0.04) (Figure 2).
CDC6 expression is reportedly present in nuclei through-
out the G1 phase of the cell cycle. CDC6 translocates to
the cytoplasm after being activated by phosphorylation
and is mainly present in the S phase of the cell cycle.
Nuclear and cytoplasmic CDC6 expressions were positive
in 23 (49%) and 16 (34%) of the 47 breast cancers and
were detected simultaneously in 11 cases (23%). How-
ever, these expressions did not significantly differ between
the high and low SUV groups of primary breast cancers (p
= 0.9 in both cases) (Figure 2).
Strong nuclear staining of Ki67 and p53 in >10% of the
cancer cells was detected in 37 (79%) and 11 (23%) of the
breast cancers, respectively. Both were significantly or
The relative expression levels were calculated against the levels of β-actin expression Figure 1
The relative expression levels were calculated against the levels of β-actin expression. Mann-Whitney test was 
performed to confirm the statistical significance of expression levels of CENP-F and CDC6 in breast cancer tissues between 
patients in low SUV group and those in high SUV group. The bars represent (A) the ratio of the expression level of CENP-F to 
that of β-actin expression level and (B) the ratio of the expression level of CDC6 to that of β-actin. Empty and filled bars rep-
resent a case of the low SUV group and high SUV group, respectively.
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almost significantly more frequent in the high SUV group
than in the low SUV group (p = 0.02 and 0.06, respec-
tively).
Seven (78%) of 9 tumors of the HER2 subtype, 4 (80%)
of 5 tumors of the triple-negative subtype were catego-
rized in the high SUV group, while 16 (48%) and 17
(52%) of 33 tumors of the luminal-A subtype were
divided in the high and low SUV groups, respectively.
Tumors of the HER2 or triple-negative subtypes were
more frequently included in the high SUV group than the
luminal-A subtype (p = 0.05) (Table 3).
Associations of clinicopathological factors and biomarkers 
with clinical outcome
Tumor invasion size, histological type, nuclear grade,
nodal status, ER, HER2, CENP-F, Ki67, and p53 were eval-
uated in the 253 primary breast cancers subjected to the
TMA analyses. There were 81 (32%) tumors with invasive
size of 2 cm or less and 172 (68%) tumors with invasive
size of more than 2 cm, 232 (92%) tumors with invasive
ductal carcinoma and 21 (8%) tumors with other types,
88 (35%) tumors with nuclear grade 3 and 154 (61%)
tumors with nuclear grade 1/2, and 112 (44%) tumors
with nodal metastasis and 141 (56%) node-negative
tumors. The positivity of ER and HER2 were 58% (148 of
253) and 10% (26 of 253), respectively.
Clinical follow-up data were retrieved in 253 patients in
disease-free survival (DFS) and 251 patients in overall sur-
vival (OS) with a mean follow-up period of 76 months (±
39.3 SD) at the time of the analysis. Because CENP-F,
Ki67, and p53 were correlated with or nearly correlated
with the SUV status of the primary breast cancer, we exam-
CENP-F (A) and Ki67 (D) exhibited immunohistochemically positive staining of nucleus in invasive ductal cancer of the breast Figure 2
CENP-F (A) and Ki67 (D) exhibited immunohistochemically positive staining of nucleus in invasive ductal can-
cer of the breast. CDC6 revealed 2 patterns of nuclear and cytoplasmic expressions in invasive ductal carcinoma of the 
breast. Positive nuclear and cytoplasmic stainings of CDC6 are presented in (B) and (C), respectively.
AB
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ined the frequency of their positivity and their prognostic
implication for these cases. The positivity of CENP-F,
Ki67, and p53 were 49% (124 of 253), 34% (87 of 253),
and 18.6% (47 of 253), respectively. Univariate analyses
revealed that a tumor size of 2 cm or more (HR = 6.7, p <
0.0001), nodal positivity (HR = 4.79, p < 0.0001), nuclear
grade 3 (HR = 3.96, p < 0.0001), a high HER2 level (HR =
2.11, p = 0.031), positive Ki67 (HR = 2.25, p = 0.0016),
positive p53 (HR = 2.35, p = 0.0024), and positive CENP-
F (HR = 3.92,p < 0.0001) revealed higher recurrence rates.
Furthermore, in a multivariate analysis, not only tumor
size of 2 cm or more (HR = 4.49, p = 0.0047) and nodal
positivity (HR = 4.1, p < 0.0001) but also positive CENP-
F (HR = 2.94, p = 0.0015) and Ki67 (HR = 2.05, p = 0.011)
showed an independent impact on the DFS of patients
(Table 4).
With regard to OS, univariate analyses revealed that nodal
positivity (HR = 9.83, p = 0.0041), nuclear grade 3 (HR =
3.73, p = 0.0019), tumor size of 2 cm or more (HR = 2.28,
p = 0.0039), and positive CENP-F (HR = 3.35, p = 0.042)
exhibited a significantly higher rate of cancer death. A
multivariate analysis with regard to OS revealed that
nodal positivity (HR = 11.88, p = 0.021) only remained an
independent predictor of patient outcome (Table 4).
In the Kaplan-Meier curves of DFS and OS in the 253
patients having primary breast cancer, curves for the
CENP-F-positive subgroup were significantly different
from those for the CENP-F-negative subgroup (p < 0.0001
and p = 0.031, respectively) (Figure 3).
Discussion
We compared the gene expression profiles between
tumors having a high level of SUV and those having a low
level of SUV, and we identified 20 candidate genes in high
SUV tumors with an mRNA expression level of greater
than 1.7-fold that in low SUV tumors by cDNA microarray
analysis. Candidate genes included genes related to cell-
cycle function, transcriptional initiation, carbohydrate
metabolism, and metastatic potential (Table 2). We con-
firmed that the 2 candidate genes CENP-F and CDC6 were
upregulated in the high SUV tumors by means of quanti-
tative RT-PCR analysis in the study of 47 resected tumors.
SUV levels are reported to be correlated with multiple fac-
tors including glucose metabolism, mitotic activity index,
and tumor cell density [13,18-20].
In the previous studies, we demonstrated that tumors with
high SUV comprised larger tumor size of invasion and
Table 4: Univariate and multivariate analyses of prognosis using pathological factors and biomarkers of primary breast cancer
Disease-free survival
Variable Univariate Multivariate
HR 95% CI p-value HR 95% CI p-value
Tumor size (&#x2267;2 cm vs <2 cm) 6.7 2.68–16.72 <0.0001 4.49 1.56–12.74 0.0047
Nodal status (+ vs -) 4.79 2.73–8.38 <0.0001 4.1 2.18–7.74 <0.0001
Nuclear grade (Grade 3 vs 1–2) 3.96 2.32–6.76 <0.0001 1.69 0.92–3.13 0.094
CENP-F (positive vs negative) 3.92 2.19–7.03 <0.0001 2.94 1.51–5.72 0.0015
p53 (positive vs negative) 2.35 1.36–4.09 0.0024 1.38 0.75–2.52 0.3
Ki67 (10% &#x2266; vs 10% >) 2.25 1.36–3.72 0.0016 2.05 1.18–3.56 0.011
HER2 (3+,FISH+ vs 0,1+,2+(FISH-)) 2.11 1.07–4.16 0.031 1.79 0.84–3.8 0.13
ER (positive vs negative) 1.54 0.94–2.52 0.087 n/a
Overall survival
Univariate Multivariate
Variable HR 95% CI p-value HR 95% CI p-value
Nodal status (+ vs -) 9.83 2.58–15.71 0.0041 11.88 1.45–97.09 0.021
Nuclear grade (Grade 3 vs 1–2) 3.73 1.25–11.15 0.0019 2.51 0.72–8.04 0.15
CENP-F (positive vs negative) 3.35 1.05–10.72 0.042 2.05 0.52–8.09 0.31
Tumor size (&#x2267;2 cm vs <2 cm) 2.28 1.3–3.99 0.0039 1.37 0.72–2.64 0.34
HER2 (3+,FISH+ vs 0,1+,2+(FISH-)) 3.02 0.84–10.85 0.09 n/a
Ki67 (10% &#x2266; vs 10% >) 2.22 0.78–6.36 0.13 n/a
p53 (positive vs negative) 1.71 0.48–6.13 0.41 n/a
ER (positive vs negative) 1.26 0.44–3.62 0.67 n/a
Abbreviations; HR, hazard ratio; CI, confidence interval; vs, versus; n/a, not applicable; positive, strong staining (2+) in 10% of cancer cells;negative, 
othersBMC Cancer 2008, 8:384 http://www.biomedcentral.com/1471-2407/8/384
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nuclear grade 3 in comparison with those with low SUV,
and for primary tumors with invasive size of 2 cm or less,
nuclear grade was the independent factor that influenced
SUV [9].
In the present study, we used cDNA microarray analysis to
demonstrate the strong relationship between SUV and
expression of CENP-F and CDC6 as cell cycle-associated
genes.
CENP-F is a nuclear protein associated with the centro-
mere-kinetochore complex, which monitors chromo-
some-microtubule interactions and serves as the source of
checkpoint signals. CENP-F gradually accumulates during
the cell cycle until it attains peak levels at the G2/M phase
and rapidly degrades upon the completion of mitosis in
vitro [21]. Thus, its expression level is considered to be
involved in M phase progression, which gradually
increases throughout the S, G2, and M phases of the cell
cycle but is absent in G0 and G1 [21,22].
CDC6 is a regulator of the early initiation of DNA replica-
tion of cancer cells in the S phase. CDC6 licenses DNA
replication, and once it is bound to the origin recognition
complex at the origins of replication, it commences
recruitment, together with Cdt1 and the MCM com-
plex[23,24]. Transcription of this protein was reported to
be regulated in response to mitogenic signals through a
transcriptional control mechanism involving E2F pro-
teins. The phosphorylated CDC6 is considered to be local-
ized in cell nuclei during the G1 phase, but it translocates
to the cytoplasm at the start of the S phase [25,26].
To confirm the expression of CENP-F and CDC6 immu-
nohistochemically, we conducted a cohort study between
the low and high SUV groups of node-negative breast can-
cer. We also examined the expression of Ki67 and p53 as
biomarkers of tumor proliferation and aggressiveness of
breast cancer.
Ki67 and p53 are well-known biomarkers of tumor prolif-
eration and aggressiveness[2]. Ki67 is a nuclear antigen of
unknown function and is detectable in cancer cells enter-
ing the cell cycle but not in the G0 phase[27]. p53 is also
implicated in the checkpoint of cell-cycle progression in
combination with DNA repair and/or induction of apop-
tosis. Most of the mutant p53 proteins are accumulated in
the nuclei and can be immunohistochemically
detected[27].
We could demonstrate significant correlations between
high SUV tumors and high CENP-F levels; however, no
correlations could be observed between high SUV tumors
with both nuclear and cytoplasmic CDC6 expressions.
According to the CENP-F expression level, some investiga-
tors have reported that CENP-F is immunohistochemi-
cally correlated with highly proliferative cancer cells and
poorer prognosis[21,22,28]. Clark et al. reported that
high CENP-F expression and tumor size were independ-
ent predictors of overall survival in a multivariate analysis
containing other prognostic factors such as tumor size,
patients age, hormonal receptors and S-phase fraction, in
386 node-negative breast cancer patients [28].
Kaplan-Meier curves of disease-free survival in 253 patients and overall survival in 251 patients with primary breast cancer as  having low or high rates of CENP-F positive cancer cells Figure 3
Kaplan-Meier curves of disease-free survival in 253 patients and overall survival in 251 patients with primary 
breast cancer as having low or high rates of CENP-F positive cancer cells. A cut-off point of 10% positive nuclei was 
used. The P value was calculated using the log-rank test.
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In a validation study of the DNA microarray dataset using
a 70-gene prognosis classifier (Mammaprint®), O'Brien et
al. reported that immunohistochemical expression of
CENP-F was an important predictor among the genes
highly expressed in breast tumors of patients with poor
overall survival[22]. The results in the present study were
mostly compatible with the previous studies discussed
above[22,28].
In the follow-up data using TMAs of primary breast can-
cer, CENP-F expression was correlated with a higher
recurrence rate and had a tendency of correlation with
mortality by cancer. As shown in Table 3, high levels of
CENP-F retained prognostic significance together with
tumor size and nodal metastasis in a multivariate
analysis.
The mRNA level of CDC6 was significantly higher in the
high SUV group than the low SUV group of primary breast
cancer (p = 0.025, Figure 1). However, the immunohisto-
chemical expression of CDC6 did not significantly differ
between both the groups. Anja et al. reported that the
increase in the CDC6 mRNA observed in the absence of
p53 was required for the enhanced proliferation of MCF-
7 cells[24]. CDC6 might be a part of a p53 protein net-
work regulating the cell cycle of cancer cells. Further, there
have been a few reports that supported the clinical impact
of immunohistochemical expression of CDC6[29,30].
Nevertheless, the clinical implications of the immunohis-
tochemical expression of CDC6 are still undetermined.
High Ki67 levels (> 10% of the labeling index) were
detected more frequently in the high SUV group than in
This figure shows the relationship of SUV with breast cancer subtypes including ER+/HER2- (luminal-A) tumors, HER2-overex- pressing tumors (HER2 subtype), and ER-/PR-/HER2- (triple-negative, including basal-like and normal breast types) tumors Figure 4
This figure shows the relationship of SUV with breast cancer subtypes including ER+/HER2- (luminal-A) 
tumors, HER2-overexpressing tumors (HER2 subtype), and ER-/PR-/HER2- (triple-negative, including basal-
like and normal breast types) tumors. Only tumors with diameter between 1.5 cm and 2.5 cm were examined. HER2- 
tumors and triple-negative tumors exhibit higher SUV levels of 5.0 (5.3 SD) and 5.0 (1.9 SD), respectively, compared to lumi-
nal-A tumors with SUV of 3.6 (2.7 SD) (p = 0.05 and 0.002, respectively).
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the low SUV group of primary breast cancer (p = 0.02,
Table 4) and correlated with shorter disease-free survival
in the univariate and multivariate analyses of DFS (p =
0.0016 and 0.011, respectively, Table 4).
High p53 levels marginally correlated with primary breast
cancers with high SUVs (p = 0.06, Table 4); however, they
were significantly related with poorer prognosis in the
univariate analysis of DFS (p = 0.024, Table 4). We assume
that primary breast cancer with high SUV is a characteristic
of aggressiveness originated from the p53 alteration, but it
seems unlikely that the immunohistochemical measure-
ment of p53 could sufficiently provide clinically useful
results because it does not exhibit p53 nonsense point
mutations or deletions in p53[31,32].
Interestingly, the majority of tumors with HER2 and tri-
ple-negative subtypes were included in the high SUV
group, while tumors of the luminal-A subtype displayed
both the high SUV and low SUV groups (Table 3). We sug-
gested tumors of the HER2 and triple-negative subtypes
might feature high proliferation activity, while the lumi-
nal-A subtype could be comprised of tumors with various
proliferation activity. We need further long-term follow-
up survey of patients and compare the prognostic impact
of SUV between the high and low SUV groups of the lumi-
nal-A tumors.
Conclusion
The present data demonstrated that high SUV in early-
stage breast cancer represents a specific biological status of
tumor cell proliferation with the upregulation of particu-
lar genes. High expression levels of the CENP-F appeared
to be the molecular background of higher proliferative
activity, and they were correlated with high SUV in breast
cancer. Therefore, high SUV levels in primary breast can-
cer may serve as a predictor of proliferation activity and
aggressiveness of tumor cells (Figure 4).
We might be able to pretherapeutically elucidate the bio-
logical characteristics of primary breast cancers by means
of FDG-PET/CT scan, and monitoring the SUV in primary
breast cancer would be informative for treatment choice
in the PST setting. Furthermore, FDG PET imaging may be
helpful to predict or identify the patients who will show a
pathological complete response following neoadjuvant
therapy.
Abbreviations
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